NewsRoom Articles - Page 2 of 217

FridayOct 10, 2025 10:00 am

How You Can Support Your Loved One Undergoing Cancer Treatment

Having a loved one diagnosed with cancer can be a very difficult time for that person and those within their immediate circle. It is often difficult to know how to support the patient during their treatment and some people make mistakes in their bid to be supportive. We discuss some suggestions that could be helpful if a loved one is undergoing cancer treatment. For starters, it is good to focus on what you are good at and offer help along those lines. Don’t try to be or do everything in your bid to help. For example, if you come from…

ThursdayOct 09, 2025 12:00 pm

Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL

The expansion of Soligenix’s European Medical Advisory Board underscores the company's commitment to delivering innovative treatment options to European patients. HyBryte (synthetic hypericin) is a first-in-class, photodynamic therapy using synthetic hypericin as a photosensitizer. The company’s efforts could establish HyBryte as a new standard of care for patients who currently have limited options. Cutaneous T-cell lymphoma (“CTCL”) is a rare but serious form of non-Hodgkin lymphoma that primarily affects the skin. Globally, millions suffer from CTCL, and in Europe, the annual incidence is estimated at 2.9 to 3.9 cases per million people (https://ibn.fm/ANk8X). Despite its rarity, CTCL presents a substantial…

ThursdayOct 09, 2025 10:00 am

Scientists Stunned Upon Discovering Glioblastoma Erodes Skull Tissue

For long, treatment approaches to glioblastoma, the deadliest form of brain cancer, have assumed that the disease is localized. However, a recent study has found that GBM erodes the skulls of its victims and this could partially explain why the current therapies have had dismal success rates against the tumors. For their study, the team analyzed scans of the skulls of mice afflicted by two types of glioblastoma. They found that the skulls were thinner than they should be. On examining scans of humans with GBM, they found altered skull thickness, especially in the areas where bones fused. The study…

WednesdayOct 08, 2025 11:15 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Expands Commercialization Strategy with $375K Financing, Investor Awareness Agreements, and Breakthrough Personalized Radiation Dose Breast CT

Izotropic Corp. marks a significant milestone in breast imaging with its patent-pending personalized radiation dose feature with the IzoView Breast CT system Recently, the company secured a $375,000 non-brokered private placement to help with core operations in addition to engaging new PR partners for improved investor communications With projections for global breast imaging expected to hit $8.69 billion by 2030, the company is poised to strategically dominate the market Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a leading medical device firm in the field of breast cancer imaging solutions, is speeding up its efforts towards commercializing its innovations. Izotropic recently…

WednesdayOct 08, 2025 10:30 am

Oncotelic Therapeutics Inc.’s (OTLC) Sapu003: Injectable Everolimus (Afinitor(R)) to Begin Clinical Trials, Aiming to Boost Drug Bioavailability

Oncotelic Therapeutics developed the Deciparticles(TM) technology to improve the bioavailability of drugs, largely thanks to the creation of sub-20nm size of the nanoparticles Sapu Nano, part of Oncotelic’s GMP Bio joint venture, receives clearance to begin Phase 1 trial of Sapu003, an injectable form of Everolimus (Afinitor(R)) for breast cancer In preclinical studies, Sapu003 could raise the bioavailability of Everolimus (Afinitor(R)) from around 10%, as oral pill, up to anywhere from 80 to 100%, as injectable Result hopes for higher bioavailability in that drugs may have dramatically better, faster, and more consistent efficacy for patients Oncotelic Therapeutics (OTCQB: OTLC) is a…

TuesdayOct 07, 2025 10:30 am

HeartBeam Inc. (NASDAQ: BEAT) Validates ECG Technology with Strong Results in Pivotal Study

HeartBeam is developing a portable, credit-card-sized device and proprietary software capable of capturing heart signals in three non-coplanar dimensions and reconstructing those signals into a full synthesized 12-lead ECG. The importance of such innovation is underscored by the widespread impact of heart disease, such as heart rhythm problems. The VALID-ECG study results carry significant weight for both clinical adoption and HeartBeam’s commercialization pathway. Early and accurate detection of heart rhythm problems can mean the difference between life-saving intervention and a missed opportunity, which is why new advances in cardiac diagnostics carry such weight. HeartBeam (NASDAQ: BEAT) has reported promising results…

TuesdayOct 07, 2025 10:00 am

Lund University Researchers Discover Why Leukemia Cells Evade the Immune System

While immunotherapy has scored a significant level of success in treating many types of cancer, it hasn’t registered similar efficacy in leukemia, especially acute myeloid leukemia, also known as AML. Researchers at Lund University, Sweden have found a possible reason why this could be so. The team sought to identify any unique surface proteins on leukemia cells that could be targeted with new forms of treatment, especially if those unique proteins didn’t exist on healthy cells. Thoas Fioretos, who led the research team, explains that they found one protein on the surface of leukemia stem cells and this particular protein…

TuesdayOct 07, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition

FDA grants NRx Pharmaceuticals approval of a Suitability Petition for single-patient preservative-free ketamine. The decision enables re-filing of an Abbreviated New Drug Application (“ANDA”) for the company’s KETAFREE(TM) product, which the company has now done. Current ketamine formulations use multidose vials with a toxic preservative, Benzethonium Chloride. U.S. ketamine market is estimated at $750 million annually, presenting a significant commercial opportunity. NRx is also advancing NRX-100 and NRX-101 for suicidal depression and PTSD, both with FDA designations. The move aligns with U.S. policy goals on reshoring drug production and reducing toxic additives. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company,…

FridayOct 03, 2025 10:00 am

Why Health Insurance Credits Led to the Federal Government Shutdown

Lawmakers in the U.S. Congress hit a stalemate in talks to keep the government open and on Wednesday, a shutdown commenced. At the core of the disagreement between GOP lawmakers and their Democratic Party counterparts are the health care tax credits in the Affordable Care Act due to expire at the end of this year and which the Big Beautiful Bill’s provisions don’t include an extension to these tax credits. A lot has been said about the cuts to Medicare and Medicaid under that law, and the refusal to renew those ACA tax credits only piles to the hardship that…

ThursdayOct 02, 2025 10:00 am

Rapid Spread of ‘Nightmare Bacteria’ Triggers Alarm

In 2013, former CDC director Tom Frieden observed that there were rising cases of ‘nightmare bacteria’, a category of bacteria characterized by three deadly attributes; resistance to all or almost all antibiotics, high mortality levels, and their ability to spread antibiotic resistance to other types of bacteria. From this triple threat of these microbes, one can understand why they are described as ‘nightmare bacteria.’ Data shows that cases of these bacteria are increasing at an alarming rate in the U.S. Available statistics indicate that there has been a nearly 70% spike in incidences of nightmare bacteria in the years 2019-2023.…